SMILES
stringlengths 2
1.49k
| Question
stringlengths 40
251
| Answer
stringlengths 1
191
|
|---|---|---|
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | What is the first recorded year of approval for this drug? | 1992 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications? | Yes |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | What is the molecular weight of this compound's parent molecule? | 366.84 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)? | No |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Is this compound an acid, a base, or neutral? | ACID |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Determine the type of availability for this drug. | prescription only |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | How many rotatable bonds does this compound have? | 2 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | How many heavy (non-hydrogen) atoms does this compound have? | 26 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Is it known whether this drug is taken orally? | Yes |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Is the drug administered in this specific form, such as a particular salt? | Yes |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | Determine if this compound is a prodrug. | No |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 1 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | What is the calculated ALogP value for this compound? | 5.51 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | How many hydrogen bond donors does this compound have? | 1 |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown. | Small molecule |
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 | What is the polar surface area (PSA) value of this compound? | 54.37 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Determine the type of availability for this drug. | discontinued |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many hydrogen bond acceptors does this compound have? | 1 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the molecular weight of this compound's parent molecule? | 318.53 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Does this compound satisfy the rule-of-three criteria? | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 0 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality. | Racemic mixture |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is it known whether this drug is applied topically? | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)? | 1 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is this compound a small molecule polymer, such as polystyrene sulfonate? | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the polar surface area (PSA) value of this compound? | 20.23 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is it known whether this drug is administered parenterally? | Yes |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M1 antagonist |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms. | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown. | Approved |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is there a black box warning associated with this drug? | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target? | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)? | 2 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications? | Yes |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the molecular formula of this compound, including any salt that it may have? | C21H36ClNO |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)? | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the calculated ALogP value for this compound? | 4.72 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound? | 0 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many aromatic rings does this compound have? | 1 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is this compound an acid, a base, or neutral? | NEUTRAL |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many heavy (non-hydrogen) atoms does this compound have? | 23 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many rotatable bonds does this compound have? | 8 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is it known whether this drug is taken orally? | Yes |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Is the drug administered in this specific form, such as a particular salt? | Yes |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Determine if this compound is a prodrug. | No |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M3 antagonist |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | How many hydrogen bond donors does this compound have? | 1 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the first recorded year of approval for this drug? | 1954 |
CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-] | What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown. | Small molecule |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality. | Single stereoisomer |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the molecular weight of this compound's parent molecule? | 325.5 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the polar surface area (PSA) value of this compound? | 23.47 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many rotatable bonds does this compound have? | 7 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Does this compound satisfy the rule-of-three criteria? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is it known whether this drug is administered parenterally? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is it known whether this drug is applied topically? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the molecular formula of this compound, including any salt that it may have? | C26H37NO7 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many hydrogen bond donors are there in this compound, calculated according to Lipinski's original rules (i.e., counting NH and OH groups)? | 1 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is this compound a small molecule polymer, such as polystyrene sulfonate? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms. | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown. | Approved |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many violations of Lipinski's Rule of Five (using HBA and HBD definitions) are there for this compound? | 1 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is there a black box warning associated with this drug? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many aromatic rings does this compound have? | 2 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many heavy (non-hydrogen) atoms does this compound have? | 24 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is it known if this drug is the first approved in its class, regardless of the indication or route of administration, acting on a specific target? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many hydrogen bond acceptors are there in this compound, calculated according to Lipinski's original rules (i.e., counting N and O atoms)? | 2 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is this drug used for therapeutic purposes, rather than for imaging, additives, or other non-therapeutic applications? | Yes |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the first recorded year of approval for this drug? | 1998 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M2 antagonist |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Has this approved drug been withdrawn due to toxicity reasons for all indications, populations, and doses in at least one country (not necessarily the US)? | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Determine the type of availability for this drug. | prescription only |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is this compound an acid, a base, or neutral? | BASE |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is it known whether this drug is taken orally? | Yes |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many hydrogen bond acceptors does this compound have? | 2 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Is the drug administered in this specific form, such as a particular salt? | Yes |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Determine if this compound is a prodrug. | No |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 1 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M3 antagonist |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | How many hydrogen bond donors does this compound have? | 1 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the calculated ALogP value for this compound? | 5.34 |
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O | What is the classification of this molecule? Please respond with Small Molecule, Protein, Antibody, Oligosaccharide, Oligonucleotide, Cell, Enzyme, Gene, or Unknown. | Small molecule |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | What is the calculated ALogP value for this compound? | 4.73 |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Determine if this drug is administered as a racemic mixture, a single stereoisomer, an achiral molecule, or has an unknown chirality. | An achiral molecule |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Does this compound satisfy the rule-of-three criteria? | No |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | How many violations of Lipinski's Rule of Five are there for this compound, using the HBA_LIPINSKI and HBD_LIPINSKI counts? | 0 |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Is it known whether this drug is applied topically? | No |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Is this compound a small molecule polymer, such as polystyrene sulfonate? | No |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | What is the molecular formula of this compound, including any salt that it may have? | C23H30BrNO3 |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | What is the first recorded year of approval for this drug? | 1953 |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Is this molecule characterized by a small molecular structure or a protein sequence? | It has a small molecule structure. |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Is it known whether this drug is administered parenterally? | Yes |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Please provide a description of this drug's mechanism of action. | Muscarinic acetylcholine receptor M1 antagonist |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Determine if this molecule is inorganic, meaning it contains only metal atoms and fewer than two carbon atoms. | No |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown. | Approved |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | How many hydrogen bond donors does this compound have? | 0 |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | What is the polar surface area (PSA) value of this compound? | 35.53 |
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-] | Is there a black box warning associated with this drug? | No |